Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV003222822 | SCV003917386 | pathogenic | not provided | 2023-02-01 | criteria provided, single submitter | clinical testing | FBN1: PM1:Strong, PM2, PM5, PP2, PP3 |
Prevention |
RCV004538925 | SCV004115794 | likely pathogenic | FBN1-related disorder | 2023-04-03 | criteria provided, single submitter | clinical testing | The FBN1 c.1746C>G variant is predicted to result in the amino acid substitution p.Cys582Trp. To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. At PreventionGenetics, this variant was identified in an individual and the similarly affected father with Marfan syndrome (internal data). This variant substitutes a cysteine residue that is located within the epidermal growth factor-like domain of the FBN1 protein. Missense variants in FBN1 that substitute or create a cysteine residue are well-documented to cause Marfan syndrome (Dietz and Dietz. 1993. PubMed ID: 20301510; Comeglio et al. 2007. PubMed ID: 17657824; Stheneur et al. 2009. PubMed ID: 19293843). Different nucleotide substitutions affecting the same amino acid (p.Cys582Arg and p.Cys582Tyr) have been reported in individuals with Marfan syndrome or congenital ectopia lentis (Attanasio et al. 2008. PubMed ID: 18435798; Chen et al. 2022. PubMed ID: 34818515). This variant is interpreted as likely pathogenic. |